Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TMDX 
TransMedics Group Inc (TMDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TMDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $142.29
1 Year Target Price $142.29
| 5 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 33.15% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.42B USD | Price to earnings Ratio 65.2 | 1Y Target Price 142.29 |
Price to earnings Ratio 65.2 | 1Y Target Price 142.29 | ||
Volume (30-day avg) 9 | Beta 2.08 | 52 Weeks Range 55.00 - 177.37 | Updated Date 08/15/2025 |
52 Weeks Range 55.00 - 177.37 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-29 | When Before Market | Estimate 0.4453 | Actual 0.92 |
Profitability
Profit Margin 13.49% | Operating Margin (TTM) 23.24% |
Management Effectiveness
Return on Assets (TTM) 5.8% | Return on Equity (TTM) 28.21% |
Valuation
Trailing PE 65.2 | Forward PE 55.56 | Enterprise Value 4541129787 | Price to Sales(TTM) 8.32 |
Enterprise Value 4541129787 | Price to Sales(TTM) 8.32 | ||
Enterprise Value to Revenue 8.55 | Enterprise Value to EBITDA 40.57 | Shares Outstanding 34090400 | Shares Floating 32960943 |
Shares Outstanding 34090400 | Shares Floating 32960943 | ||
Percent Insiders 3.01 | Percent Institutions 120.52 |
Upturn AI SWOT
TransMedics Group Inc
Company Overview
History and Background
TransMedics Group, Inc. was founded in 1998. It focuses on developing and delivering innovative organ care system (OCS) technology to preserve and assess organs for transplant. Its initial focus was on heart transplantation, later expanding to lungs and livers. Significant milestones include FDA approvals for its OCS technology for various organs.
Core Business Areas
- Organ Care System (OCS) Heart: Provides a portable system for preserving and assessing donor hearts outside the human body during transport for transplantation.
- Organ Care System (OCS) Lung: A portable system for preserving and assessing donor lungs outside the human body during transport for transplantation.
- Organ Care System (OCS) Liver: A portable system for preserving and assessing donor livers outside the human body during transport for transplantation.
- National OCS Program (NOP): A logistics and clinical service offering around the OCS platform to enable hospitals to procure donor organs.
Leadership and Structure
Waleed Hassanein, MD, is the President and Chief Executive Officer. The company has a board of directors and a management team responsible for overseeing various functions, including research and development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- OCS Heart System: The OCS Heart System maintains donor hearts in a near-physiologic state, allowing for assessment and potentially increasing the number of viable hearts for transplantation. While precise market share data is difficult to obtain, TransMedics is a leader in this emerging field. Competitors include traditional cold storage methods and companies exploring other perfusion technologies.
- OCS Lung System: The OCS Lung System preserves and assesses donor lungs, potentially increasing the number of lungs suitable for transplantation. Similar to the heart system, market share data is not readily available, but TransMedics is a key player. Competitors include traditional cold storage and other organ preservation solutions. Revenue is significant but precise figures are not publicly shared.
- OCS Liver System: The OCS Liver System preserves and assesses donor livers, aiming to improve outcomes for liver transplant recipients. Market share data is limited, but the company has a substantial position in this emerging field. Revenue is significant but precise figures are not publicly shared. Competitors include traditional cold storage and other organ preservation solutions.
Market Dynamics
Industry Overview
The organ transplantation industry faces a chronic shortage of viable donor organs. Technologies that improve organ preservation and assessment are highly valuable. The industry is driven by increasing demand for transplants and advancements in medical technology.
Positioning
TransMedics is positioned as a leader in the organ preservation and assessment technology space, particularly with its OCS technology. Its competitive advantage lies in its proprietary technology and clinical data supporting improved transplant outcomes.
Total Addressable Market (TAM)
The TAM is estimated to be in the billions of dollars, encompassing the costs associated with organ transplantation, organ preservation, and related medical procedures. TransMedics is well-positioned to capture a significant portion of this TAM as its technology becomes more widely adopted.
Upturn SWOT Analysis
Strengths
- Proprietary OCS Technology
- FDA approvals for multiple organ types
- Clinical data supporting improved outcomes
- Strong brand recognition in the organ transplantation field
- Established National OCS Program (NOP)
Weaknesses
- High cost of OCS technology
- Reliance on regulatory approvals
- Limited market penetration compared to traditional methods
- Dependence on key personnel
Opportunities
- Expanding OCS use to more transplant centers
- Developing OCS technology for other organ types
- Securing reimbursement coverage from payers
- Growing international presence
- Partnering with transplant organizations and hospitals
Threats
- Competition from alternative organ preservation technologies
- Changes in regulatory landscape
- Economic downturn impacting hospital budgets
- Product liability claims
- Disruptive new technologies
Competitors and Market Share
Key Competitors
- CSII
- ORGN
- ALVR
Competitive Landscape
TransMedics has a competitive advantage in its OCS technology, but faces competition from companies offering alternative organ preservation and transplantation solutions. The company needs to focus on expanding market share and securing reimbursement coverage to maintain its leadership position.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased adoption of OCS technology and expansion into new organ types.
Future Projections: Analyst estimates project continued revenue growth driven by market penetration and expansion of OCS applications.
Recent Initiatives: Recent initiatives include expanding the National OCS Program, securing reimbursement coverage, and developing new OCS applications.
Summary
TransMedics Group Inc. is a leader in organ preservation technology with its innovative OCS system and National OCS Program. The company has secured regulatory approvals and demonstrated improved transplant outcomes. While the high cost of technology and dependence on approvals pose challenges, the company has growth potential through market penetration and expansion into new organ types. Key watchouts include increased competition and economic conditions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TransMedics Group Inc
Exchange NASDAQ | Headquaters Andover, MA, United States | ||
IPO Launch date 2019-05-02 | Founder, President, CEO & Director Dr. Waleed H. Hassanein M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 728 | Website https://www.transmedics.com |
Full time employees 728 | Website https://www.transmedics.com | ||
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.